1997.-Polymorphonuclear neutrophils (PMN) and platelets interact to produce both inflammatory and anti-inflammatory lipid mediators during human disease. Because swine models of human disease are used, it is important to understand the mechanisms involved in the formation of lipid mediators from porcine PMN-platelet interactions.
In the present study, we investigated the mechanism of thromboxane (TX) A2 and lipoxin A4 (LXAd) formation from porcine PMN and platelets, respectively. PMN (107/ml) and platelet (30 X 107/ml) suspensions stimulated with porcine C5a (pCF>a), but not recombinant human C5a (rhC%a), significantly enhanced TxB2 formation. After cytochalasin B treatment, pC5a or rhC5a significantly and equally enhanced TxB2 formation from PMN-platelet suspensions. A-23187-induced TxBz formation from platelets was not significantly augmented by the presence of PMN in these suspensions. A-23187 induced significant LXAJ production from porcine PMN that was not augmented by addition of platelets. Flow cytometric analysis of PMN-platelet suspensions revealed activated platelets adherent to PMN following pC5a stimulation.
CV-6209, a plateletactivating factor (PAF) receptor antagonist, dose dependently prevented pC5a-induced platelet adherence to PMN and TxBz formation.
These data demonstrate that 1) porcine PMN alone can biosynthesize LXA4 without the assistance of platelets, which is in sharp contrast to human PMN-platelet interactions, and 2) in the absence of cytochalasin B, pC5a stimulates PAF biosynthesis from porcine PMN, resulting in TxB2 formation from platelets. thromboxane;
lipoxins; C5a; A-23187 ANIMAL MODELS OF HUMAN disease are useful in understanding the roles and mechanism of action of mediators in the disease process. Swine are used in many different models of human disease or clinical situations, including ischemia-reperfusion injury, cardiopulmonary bypass, restenosis, and hemodialysis. However, using swine models of human disease requires an understanding of the similarities and differences that exist in signaling events between porcine cells compared with human cells and the mechanisms of mediator production and/or biosynthesis. For example, human polymorphonuclear neutrophils (PMN) display chemotaxis to N-formyl-Met-Leu-Phe (f-MLP) or various species forms of the anaphylatoxin C5a, including rat, rabbit, guinea pig, and swine (2, 4). On the other hand, porcine PMN have been shown to be essentially unresponsive to f-MLP or zymosan-activated human, rabbit, or guinea pig sera (i.e., source of C5aKZa des Arg)-induced chemotaxis (2,9). Similarly, porcine PMN contain 12-lipoxygenase and &lipoxygenase, whereas human PMN only contain 5-lipoxygenase (8) . These data suggest that signaling and production of lipid mediators (LM) by porcine PMN may differ sharply compared with human PMN.
Activation of human neutrophils (PMN) in the presence of platelets leads to an interaction that results in the biosynthesis of LM. The primary biosynthesis of LM results from transcellular metabolism (e.g., lipoxins), cell-cell cross talk [e.g., thromboxane A2 (TxAJJ, and/or cellular biosynthesis [e.g., platelet-activating factor (PAF)] (7, 8, 18, 26) . Each of these LM can be further increased by cytokine priming (26). These LM are proinflammatory (e.g., PAF), anti-inflammatory (e.g., lipoxins), and possess vasoactivity (e.g., TxA2, lipoxins, and PAF) (8, 17, 18, 26) . Thus understanding the biosynthetic pathways of these molecules is crucial to the development of novel therapeutics (i.e., agonists, antagonists, and enzyme inhibitors), which display organ, tissue, and species selectivity.
Costimulation of human PMN and platelets with recombinant human C5a (rhC5a) has been shown to produce the proinflammatory mediator Tx& but only in the presence of cytochalasin B (7). The mechanism of platelet activation, secretion, and thromboxane production from human PMN-platelet cosuspensions following rhC5a stimulation appears to require the release of cathepsin G from azurophilic granules, followed by upregulation of CD62P, platelet adherence on PMN, and arachidonic acid transfer (6, 7, (20) (21) (22) . Costimulation of human PMN and platelets, in the absence of cytochalasin B, can also result in the transcellular formation of the anti-inflammatory LM, lipoxins (8, 18, 26) . Thus costimulation of human PMN and platelets produces pro-and anti-inflammatory LM. We have previously observed that costimulation of porcine PMN and platelets with porcine C5a (pC5a) synthesized TxA2 in the absence of cytochalasin B (10). These data suggested that the mechanism of thromboxane production from porcine PMN-platelet suspensions differed from that previously shown by others for human cells. Thus, in the present study, we investigated the mechanism of pC5a-induced thromboxane formation from porcine PMN, platelets, and cosuspensions. Because thromboxane production may have involved transcellular metabolism, we monitored lipoxin A4 (LX&) production to gain insight into the generation of inflammatory (TxA2) and anti-inflammatory (lipoxins) LM from porcine cells. We also compared pC5a-, rhC5a-, and A-23187-induced LXA4 and thromboxane formation from porcine PMN, platelet, and PMN-platelet suspensions and correlated thromboxane formation with flow cytometric analysis of cellular suspensions. for 5 min at 4°C. The activated plasma was acidified to 1 N with HCl for 20 min, followed by addition of ammonium sulfate (50%). The suspension was centrifuged (4"C), dialyzed against ice-cold distilled HZ0 (40 liters) overnight, and then lyophilized.
The lyophilized material was reconstituted with 0.1 mol./l formic acid (pH 7.2) and applied to SP Sepharose at 4°C. The column was washed with 0.1 mol/l formic acid (pH 7.2). C5a was eluted with a linear gradient of formic acid (pH 7.2) from 0.1 to 0.5 mol/l at 0.2 ml/min (300 ml total volume). Collected fractions (2.3 ml) were analyzed by an antibody capture enzyme-linked immunosorbent assay (ELISA), using a monoclonal antibody against pC5a (I, 5). Fractions containing pC5a were pooled, dialyzed against distilled HZ0 for 24 h at 4"C, lyophilized, and resuspended in distilled HZO. Reduced and nonreduced samples were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), using rhC5a (Sigma Chemical) and pC5a (gift from Dr. Richard Johnson) as internal standards. Purified pC5a gave a single band on the SDS-PAGE gel with a molecular weight consistent with that of the two separate C5a standards.
The purity of the pC5a was assessed by amino acid analysis (Harvard Microchemistry Department) to rule out contamination with C5a des Arg. The correct ratio of amino acid residues for the known pC5a sequence was observed (32). Furthermore, NHZ-terminal sequencing (Harvard Microchemistry Department) of the pC5a demonstrated the correct sequence for the first eight amino acid residues (II). Thus the purity and concentration of the pC5a were established.
The purity of rhC5a was as stated by the manufacturer (Sigma Chemical). PMN and platelet isolation. Porcine neutrophils and platelets were isolated from the arterial blood sample, as described previously in Ref.
10. Briefly, ACD-anticoagulated porcine blood was mixed with 4% gelatin (Sigma Chemical) in 0.9% NaCl and allowed to settle at 37°C for 30 min. The supernatant was then layered over Histopaque-1083 separation media (Sigma Chemical) and centrifuged at 400 g for 25 min at room temperature.
The neutrophils were isolated from the resultant pellet after hypotonic lysis of the red blood cells and suspended in Hanks' balanced salt solution without calcium, magnesium, or phenol (mHBSS; Sigma Chemical). PMN isolates contained typically >97% neutrophils with 2.6 ? 0.5 platelets/l00 PMN and 2.3 rt 0.4% mononuclear white blood cells. Platelets were isolated from the monocyte-lymphocyte layer after centrifugation and suspended in mHBSS containing 0.1% bovine serum albumin (BSA). Platelet isolates contained 6.4 t: 0.5 PMN/l,OOO platelets. Cell viability (>95%) was assessed by trypan blue exclusion. Purity and concentration of cells were determined by a hemocytometer and Coulter counter (MicroDiff 16, Miami, FL) . Stimulation of eicosanoid formation by rhC5a, A-23187, or pC5a. Suspensions containing PMN (107/ml), platelets (30 X 107/ml), or platelets (30 x 107/ml) and PMN (107/ml) in mHBSS containing 0.1% BSA were placed in a polypropylene test tube and warmed (37°C) for 1 min. The sample was equally divided and placed in a cuvette and stirred in a platelet aggregometer (Chronolog) at 37°C. Porcine PMN (107/ml) were incubated with cytochalasin B (5 pg/ml) for 3 min in some experiments, and the cells were washed and resuspended with platelets (30 X 107/ml). The samples were then stimulated with pC5a (10 nmol/l), rhC5a (10 nmol/l), A-23187 (5 pmol/l), or vehicle (0.1% BSA). The final volume in all the assays was 0.5 ml. EDTA(750 pg in 5 ~1) was added to each sample after 5 min. The sample was then centrifuged (2,OOOg at 4°C for 20 min), and the supernatant was removed and frozen at -80°C until assayed for thromboxane Bz (TxB,) and/or LXA,+ PMN-platelet concentration-dependent TxBz formation. A suspension containing PMN, platelets, or platelets plus PMN in mHBSS containing 0.1% BSA was placed in a polypropylene test tube and warmed (37°C) for 1 min. PMN (107cells/ml) were added to platelet concentrations of 3 X 108, 2 X 108, 1 X 10s, I X 107, or 1 X IO6 cells/ml in one set of experiments.
The suspension was then divided equally and placed in a stirred cuvette in a platelet aggregometer (Chronolog) at 37°C. The samples were then stimulated with pC5a (10 nmol/l) or vehicle. Platelets (3 X IO8 cells/ml) were added to PMN concentrations of 1 X 107, 1 X 106, or 1 X IO5 cells/ml in another set of experiments.
The final volume in all the assays was 0.5 ml. EDTA (750 pg in 5 ~1) was added to each sample after 5 min. The sample was then centrifuged (2,000 g at 4°C for 20 min), and the supernatant was removed and subsequently frozen at -80°C until assayed for TxB2.
Flow Each suspension was then divided equally and treated with pC5a (10 nmol/l) or vehicle as described above (Stimulation of eicosanoid formation by rhC5a, A-23187, or pC5a). EDTA (750 pg) was added to each test tube after 5 min. Samples were centrifuged at 2,000 g for 20 min at 4"C, and the supernatants were removed and stored at -80°C until assayed for TxB 2. Some samples were also fixed and analyzed by FACS as described above. TxB2 formation in platelets from pC5a-stimulated PMN supernatant.
PMN ( lo8 cells/ml mHBSS or lo8 cells/ml mHBSS containing 0.1% BSA) were incubated with either pC5a (100 nmol/l) or vehicle for 5 min at 37"C, followed by centrifugation. The supernatants (50 ~1) were added to platelet suspensions (2 X lo8 cells/ml) in 450 ,ul mHBSS (note that pC5a and PMN concentrations were increased lo-fold because of this 1:lO dilution).
PMN ( lo7 cells/ml) and platelet suspensions (2 X lo8 cells/ml) were stimulated with either pC5a (10 nmoLl) or vehicle and served as positive and negative controls for these experiments, respectively. EDTA was added to each PMN and/or platelet sample after 5 min. Samples were centrifuged and stored at -80°C until assayed for TxB2. Enzyme-linked immunosorbent assays. Samples were assayed by ELISA (ELISA Technologies) for TxBz and LXA4, as previously described in Refs. 10 and 27. The lower limits for TxBg and LXA4 detection were 0.01 and 0.03 pmol/ml, respectively.
Data analysis. Data are expressed as means t SE. Analysis was performed with SigmaSTAT (Jandel Scientific, San Rafael, CA). Differences within groups were assessed by analysis of variance. All pairwise multiple comparisons were made with the Student-Newman-Keuls test.
RESULTS
CSa-induced TxB2 production. Addition of pC5a or rhC5a (10 nmol/l) to isolated porcine PMN (107/ml) or platelets (30 x 10Vml) independently failed to stimulate production of significant amounts of TxBz (Fig. 1) . In contrast, addition of pC5a (10 nmol/l) to coincubations of porcine PMN and platelet suspensions induced significant TxB2 formation. Addition of rhC5a (10 nmol/l) to coincubations of porcine PMN and platelet suspensions yielded significantly less TxB2 compared with pC5a. PMN aggregation induced by rhC5a (10 nmol/l) was comparable to pC5a (10 nmol/I)-induced aggregation (81 t 8% vs. 71 2 8%, respectively).
Previous studies demonstrated that costimulation of human PMN and platelets with rhC5a required cytochalasin B to induce TxB2 formation (7). Incubation of porcine PMN with cytochalasin B (5 lug/ml) before stimulation with rhC5a or pC5a also failed to increase TxBz formation (Fig. 1B) . Platelets incubated with cytochalasin B-treated PMN significantly increased TxB2 formation following either pC5a or rhC5a stimulation. We observed a three-and sevenfold increase in TxB2 formation following pC5a and rhC5a stimulation compared with non-cytochalasin B-treated PMN, respectively. The amount of rhC5a-induced TxB2 formation was not significantly different from pC5a-induced TxBz formation in the presence of cytochalasin B-treated PMN.
A-23187induced eicosanoid production. Similar to C5a, the calcium ionophore, A-23187 (5 pmol/l), also did not induce TxB2 formation from isolated porcine PMN (Fig. 2) . Unlike pC5a or rhC5a, A-23187 significantly increased TxB2 formation from isolated platelets. However, unlike pC5a, addition of PMN to platelets failed to augment significantly TxBz formation followingAstimulation.
We monitored LXA4 biosynthesis because it is a product of transcellular biosvnthesis from human PMN- Fig.  3 . We observed a statistically significant increase in LXA4 biosynthesis from porcine PMN but not from isolated porcine platelets. Addition of platelets to the PMN did not augment LXA4 biosynthesis.
LXA4 generation was -30-fold less than TxB2 generation after A-23187 treatment of PMN and platelet suspensions. Stimulation of porcine PMN with pC5a (10 nmol/l) produced a significant increase in LXAd biosynthesis (0.06 t 0.03 pmol/ml) after 5 min of stimulation, which was significantly less than A-23187-induced LXA4 biosynthesis.
The pC5a-induced LXA4 biosynthesis from PMN was not observed following stimulation of PMNplatelet suspensions, suggesting that the major LM produced after porcine PMN-platelet interactions is TxB2.
Influence of platelet-to-PMN ratio. Because rhC5a failed to induce biosynthesis of significant amounts of TxB2 from PMN and platelet suspensions, the mechanism of pC5a-induced TxB2 formation from PMN and platelet suspensions was investigated by examining the influence of platelet-to-PMN ratios in vitro. pC5a-induced TxB2 formation increased in a concentrationdependent manner as the platelet concentration increased while the PMN was maintained at lo7 cells/ml (Fig. 4) . Addition of lo6 platelets/ml to PMN (107/ml) significantly increased TxB2 formation compared with pC5a stimulation of PMN alone. Maximal TxBz formation was observed with a platelet-to-PMN ratio of ZO-30:l.
The role of PMN in pC5a-induced TxBz formation from PMN-platelet suspensions is illustrated in Fig. 5 . Platelets (30 X 107/ml) alone failed to induce TxB2 formation in the absence of PMN following pC5a stimulation. pC5a significantly increased TxB2 formation from platelets (30 X 107/ml) in the presence of lo6 PMN/ml (i.e., platelet-to-PMN ratio equals 300 the platelet-to-PMN ratio was decreased to 30, maximal TxBz formation was observed.
Role of PAF in TxB2 formation. Previous studies with rabbit or human PMN-platelet suspensions have demonstrated a role for PAF-induced TxB2 formation after stimulation with f-MLP or rhC5a (3, 7). The PAF receptor antagonist CV-6209 concentration dependently inhibited TxB2 formation from pC5a-stimulated PMN and platelet suspensions (Fig. 6) . A significant reduction in TxBz formation was observed at 16 and 160 pmol/l CV-6209 compared with untreated cellular suspensions (i.e., 0 in Fig. 6 ). These data suggest that PAF plays an important role in pC5a-induced TxBz formation from PMN and platelet suspensions. PAF has been demonstrated to be released into the supernatant of stimulated PMN in the absence of a carrier protein to activate platelets (31). We investigated whether PAF was released into the supernatant of pC5a-stimulated PMN in the presence and absence of 0.1% BSA. Supernatant (50 ~1) from pC5a-stimulated PMN (lOs/ml HBSS) synthesized similar concentrations of TxB2 from 20 X lo7 platelets/ml compared with pC5a-stimulated PMN (107/ml) and platelet (20 X 107/ml) suspensions (Fig. 7) . CV-6209 (16 pmol/l) treatment of platelets 5 min before supernatant addition significantly attenuated TxBz formation to 5.6 ~fr 2. pmol/ml (n = 4; P < 0.05 compared with non-CV-6209 treatment).
Interestingly, supernatant from pC5a-stimulated PMN (1OYml) bathed in 0.1% BSA synthesized significantly less TxBz compared with PMN bathed in HBSS. These data suggest that PAF is released into the supernatant in the absence of a carrier protein following pC5a stimulation of porcine PMN.
Flow cytometry data. From these data, we hypothesized that platelet interactions with pC5a-activated PMN occur through a PAF-dependent pathway in vitro. We next examined whether pC5a influences PMNplatelet adhesion and the specific role of PAF. The presence of platelets adherent to pC5a-activated PMN was investigated by flow cytometry using a rabbit polyclonal antibody (PAb) to porcine CD62P and gating for porcine PMN (Fig. 8, A and B) . PMN and platelet suspensions stained with the negative control PAb (i.e., rabbit anti-horse immunoglobulin) yielded a mean fluorescence intensity (MFI) of 4.7 ? 0.1 arbitrary units. PMN and platelet suspensions stained with the PAb to porcine CD62P in the absence of pC5a stimulation yielded an MFI of 16.8 _ + 0.3 arbitrary units (Fig. 8A) . MFI significantly increased to 63.7 ? 0.6 arbitrary units following pC5a stimulation. In other experiments (Fig. 8B) , we observed a significant increase in MFI in unstimulated PMN-platelet suspensions from 21.2 ? 0.3 to 57.8 I~I 1.1 arbitrary units following pC5a (10 nmol/l) stimulation. Treatment with CV-6209 (16 pmol/l) reduced the MFI from 57.8 t 1.1 to 28.7 t 0.5 arbitrary units following pC5a stimulation (Fig. 8B ). These data demonstrate that platelet adherence to pC5a-stimulated PMN is dependent on PAF.
DISCUSSION
Several observations were made during the course of this study that have a significant impact on the role of PMN-platelet interaction and eicosanoid biosynthesis in porcine models. Stimulation of purified populations of porcine PMN withA-23187, pC5a, or rhC5a failed to induce TxB2 formation, suggesting that porcine PMN, like human PMN, do not express a functional cyclooxygenase. Stimulation of porcine platelets alone with A-23187, but not pC5a or rhC5a, significantly increased TxB2 formation. Costimulation of PMN and platelets with pC5a, but not rhC5a, synthesized significantly more TxB2 than PMN or platelets alone, even though rhC5a induced PMN aggregation. Cytochalasin B treatment of PMN significantly enhanced pC5a-induced TxBz formation from PMN-platelet suspensions and induced rhC5a-mediated TxB2 formation. Unlike pC5a, A-23187-induced TxB2 formation from isolated platelets was not augmented by the presence of PMN. A-23187 also directly biosynthesized LXA4 from isolated porcine PMN, but platelets did not augment LXA, biosynthesis. The optimal platelet-to-PMN ratio for pC5a-induced TxB2 formation was -lo-3O:l.
The PAF receptor antagonist, CV-6209, concentration dependently inhibited TxB2 formation from pC5a-stimulated PMN-platelets suspensions. CV-6209 also inhibited TxB2 formation from platelets treated with supernatant from pC5a-stimulated PMN. FACS analysis dem- have shown that porcine PMN exposed to secreted These data suggest that pC5a, and to a significantly phospholipase A2 or A-23187 produced lipoxin B4 and lesser extent rhCEia, activate porcine PMN and produce lesser amounts of LXA4. Also, Hada and colleagues (12) PAF that remains associated to the PMN membrane, have shown that porcine PMN 12-lipoxygenase, like which is followed by platelet adherence and/or activahuman platelet 12-lipoxygenase (24), can convert leukotion and TxB2 formation. In the absence of a carrier triene A4 into lipoxins. Thus porcine PMN appear to protein (i.e., BSA), PAF is released into the supernagenerate LXAd by a 5-lipoxygenase and 12-lipoxygetant to activate platelets and produce TxB2.
nase pathway from endogenous sources. In the present rhC5a produced significantly less TxB2 in PMN and study, porcine PMN produced significant amounts of platelet suspensions compared with pC5a in the ab-LXA4 following A-23187, and to a lesser extent pC5a, 
